vs
Side-by-side financial comparison of Aclaris Therapeutics, Inc. (ACRS) and T Stamp Inc (IDAI). Click either name above to swap in a different company.
Aclaris Therapeutics, Inc. is the larger business by last-quarter revenue ($1.3M vs $908.9K, roughly 1.4× T Stamp Inc). On growth, T Stamp Inc posted the faster year-over-year revenue change (-39.3% vs -85.9%). T Stamp Inc produced more free cash flow last quarter ($2.0M vs $-47.2M). Over the past eight quarters, T Stamp Inc's revenue compounded faster (25.9% CAGR vs -26.5%).
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
T Stamp Inc, trading under ticker IDAI, develops AI-powered identity verification, trust scoring, and fraud prevention solutions. It serves clients across fintech, healthcare, and e-commerce segments, primarily operating in North America to help organizations securely authenticate user identities and mitigate fraud risks.
ACRS vs IDAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $908.9K |
| Net Profit | — | $-2.5M |
| Gross Margin | 58.9% | — |
| Operating Margin | — | -224.9% |
| Net Margin | — | -279.9% |
| Revenue YoY | -85.9% | -39.3% |
| Net Profit YoY | 79.5% | 57.7% |
| EPS (diluted) | — | $-0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $908.9K | ||
| Q3 25 | $3.3M | $872.5K | ||
| Q2 25 | $1.8M | $812.7K | ||
| Q1 25 | $1.5M | $545.5K | ||
| Q4 24 | $9.2M | $1.5M | ||
| Q3 24 | $4.3M | $511.1K | ||
| Q2 24 | $2.8M | $500.4K | ||
| Q1 24 | $2.4M | $573.7K |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-14.6M | $-1.9M | ||
| Q2 25 | $-15.4M | $-1.7M | ||
| Q1 25 | $-15.1M | $-2.2M | ||
| Q4 24 | $-96.6M | $-6.0M | ||
| Q3 24 | $-7.6M | $-1.3M | ||
| Q2 24 | $-11.0M | $-2.6M | ||
| Q1 24 | $-16.9M | $-2.7M |
| Q4 25 | 58.9% | — | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 71.0% | — | ||
| Q1 25 | 65.2% | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 66.3% | — |
| Q4 25 | — | -224.9% | ||
| Q3 25 | -519.8% | -203.0% | ||
| Q2 25 | -1035.9% | -207.0% | ||
| Q1 25 | -1242.9% | -396.5% | ||
| Q4 24 | -1082.3% | -81.2% | ||
| Q3 24 | -240.9% | -523.7% | ||
| Q2 24 | -464.7% | -524.7% | ||
| Q1 24 | -789.4% | -496.7% |
| Q4 25 | — | -279.9% | ||
| Q3 25 | -443.0% | -219.1% | ||
| Q2 25 | -868.3% | -210.7% | ||
| Q1 25 | -1036.8% | -395.5% | ||
| Q4 24 | -1048.3% | -401.5% | ||
| Q3 24 | -174.6% | -245.7% | ||
| Q2 24 | -397.2% | -519.3% | ||
| Q1 24 | -706.5% | -466.9% |
| Q4 25 | — | $-0.37 | ||
| Q3 25 | $-0.12 | $-0.72 | ||
| Q2 25 | $-0.13 | $-0.69 | ||
| Q1 25 | $-0.12 | $-0.89 | ||
| Q4 24 | $-1.21 | $-3.14 | ||
| Q3 24 | $-0.11 | $-1.06 | ||
| Q2 24 | $-0.15 | $-3.19 | ||
| Q1 24 | $-0.24 | $-3.97 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $6.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $103.1M | $8.7M |
| Total Assets | $160.5M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.0M | $6.0M | ||
| Q3 25 | $25.3M | $5.4M | ||
| Q2 25 | $25.4M | $292.1K | ||
| Q1 25 | $30.4M | $1.1M | ||
| Q4 24 | $24.6M | $2.8M | ||
| Q3 24 | $47.7M | $598.0K | ||
| Q2 24 | $22.8M | $659.5K | ||
| Q1 24 | $35.8M | $816.7K |
| Q4 25 | $103.1M | $8.7M | ||
| Q3 25 | $120.1M | $6.1M | ||
| Q2 25 | $131.7M | $2.4M | ||
| Q1 25 | $144.1M | $4.1M | ||
| Q4 24 | $155.6M | $3.0M | ||
| Q3 24 | $130.2M | $5.4M | ||
| Q2 24 | $133.8M | $750.4K | ||
| Q1 24 | $142.0M | $1.4M |
| Q4 25 | $160.5M | $11.2M | ||
| Q3 25 | $175.5M | $11.2M | ||
| Q2 25 | $189.1M | $5.7M | ||
| Q1 25 | $198.1M | $6.6M | ||
| Q4 24 | $220.3M | $8.6M | ||
| Q3 24 | $182.4M | $10.6M | ||
| Q2 24 | $161.1M | $5.2M | ||
| Q1 24 | $174.1M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.1M | $2.0M |
| Free Cash FlowOCF − Capex | $-47.2M | $2.0M |
| FCF MarginFCF / Revenue | -3646.6% | 215.4% |
| Capex IntensityCapex / Revenue | 8.6% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-81.3M | $-5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.1M | $2.0M | ||
| Q3 25 | $-10.9M | $-4.0M | ||
| Q2 25 | $-10.0M | $-2.1M | ||
| Q1 25 | $-13.1M | $-1.5M | ||
| Q4 24 | $-8.9M | $-2.7M | ||
| Q3 24 | $22.0M | $-2.4M | ||
| Q2 24 | $-12.3M | $-1.6M | ||
| Q1 24 | $-20.8M | $-2.2M |
| Q4 25 | $-47.2M | $2.0M | ||
| Q3 25 | $-11.0M | $-4.0M | ||
| Q2 25 | $-10.0M | $-2.1M | ||
| Q1 25 | $-13.1M | $-1.6M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-12.3M | $-1.6M | ||
| Q1 24 | $-20.9M | $-2.2M |
| Q4 25 | -3646.6% | 215.4% | ||
| Q3 25 | -332.1% | -459.6% | ||
| Q2 25 | -563.5% | -258.6% | ||
| Q1 25 | -900.3% | -289.2% | ||
| Q4 24 | — | -182.9% | ||
| Q3 24 | — | -475.4% | ||
| Q2 24 | -446.0% | -320.9% | ||
| Q1 24 | -873.6% | -376.6% |
| Q4 25 | 8.6% | 0.8% | ||
| Q3 25 | 0.7% | 0.0% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 3.0% | 6.8% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.5% | 1.3% | ||
| Q1 24 | 5.6% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
